Is Hysingla ER affected by genetics?
Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.
Hysingla ER is affected by pharmacogenetics through the CYP2D6 gene. Your genotype for this gene can change how well Hysingla ER works for you or how well you tolerate it. The strongest evidence level on this page is Strong, from the published guidelines shown below.
What's in Hysingla ER
Hydrocodone Affected by CYP2D6
Affected by CYP2D6. Guidance from CPIC, strong evidence.
Read the full hydrocodone genetics guideHydrocodone phenotype recommendations
Published guidance from CPIC on how hydrocodone should be dosed or substituted based on your CYP2D6 phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
| Ultrarapid MetabolizerCYP2D6 | There isn't enough evidence to say whether your result changes how hydrocodone works for you, so the guideline makes no recommendation. | CPIC No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia. |
Not rated |
| Normal MetabolizerCYP2D6 | Your body processes hydrocodone normally, so the usual dose is expected to work. | CPIC Use hydrocodone label recommended age- or weight-specific dosing. |
Strong |
| Intermediate MetabolizerCYP2D6 | The usual dose is recommended. If it doesn't relieve your pain, a different pain medicine may be considered. | CPIC Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid. |
Optional |
| Poor MetabolizerCYP2D6 | Your body makes less of hydrocodone's stronger active form. It's not clear this changes pain relief, so the usual dose is recommended, with a different pain medicine to consider if it doesn't work. | CPIC Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid. |
Optional |
| IndeterminateCYP2D6 | The impact of your genotype on response to this drug is unknown. | CPIC Initiate therapy with recommended starting dose. |
Not rated |
| Not availableCYP2D6 | The impact of your genotype on response to this drug is unknown. | CPIC Initiate therapy with recommended starting dose. |
Not rated |
Source: CPIC
The gene behind the guidance
CYP2D6 Cytochrome P450 2D6
CYP2D6 is the most clinically important pharmacogene. It metabolizes around a quarter of all prescription drugs, including many antidepressants, opioids, and stimulants. The gene is unusually variable: roughly 7 percent of people are poor metabolizers (they barely activate CYP2D6), and another 1 to 3 percent are ultrarapid metabolizers (their enzyme is overactive).
The v4 report preserves the activity score used in its interpretation. Some medicines use a combined CYP2D6/CYP2C19 recommendation. CYP2D6 inhibitors can change functional metabolism; a genotype alone does not capture that effect.
See all drugs affected by CYP2D6Browse the full drug class: Pain medications.
Related medications
Find out how your genetics affect Hysingla ER
Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.